PCN59 Cost-Effectiveness of Pazopanib Versus Sunitinib and Bevacizumab Associated to Interferon Alpha As First Line Treatments for Metastatic Renal Cell Carcinoma
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.1176
https://www.valueinhealthjournal.com/article/S1098-3015(12)01241-7/fulltext
Title :
PCN59 Cost-Effectiveness of Pazopanib Versus Sunitinib and Bevacizumab Associated to Interferon Alpha As First Line Treatments for Metastatic Renal Cell Carcinoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01241-7&doi=10.1016/j.jval.2012.03.1176
First page :
A218
Section Title :
Cancer
Open access? :
No
Section Order :
698